Last reviewed · How we verify

NCT07342608: STARLIGHT

Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum

Not yet recruiting NA Last updated 17 February 2026
What this trial tests

NA trial testing Use of LINEA cardiac pacing lead in Bradycardia in 450 participants. Not yet recruiting.

Timeline
31 March 2026
Primary endpoint
31 January 2027
30 April 2030

Quick facts

Lead sponsorMicroPort CRM
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment450
Start date31 March 2026
Primary completion31 January 2027
Estimated completion30 April 2030

Drugs / interventions tested

Conditions studied

Sponsor

MicroPort CRM — full company profile →

Who can join

18 and older, any sex, with Bradycardia or Left Bundle Branch Area Pacing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bradycardia

Currently open trials in the same condition.

Other MicroPort CRM trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07342608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing